334 A phase I study is ongoing to evaluate AG-270 in advanced solid tumors and lymphomas (NCT03435250)
Enjoy your IV therapy in the comfort of our plush reclining chairs while listening to calming music or adding on one of our treatments such as oxygen therapy, light therapy or audio visual entrainment
-
Sample type considerations Different biological matrices have different detection characteristics: Urine: Most common testing matrix, metabolites accumulate Blood/plasma: Shorter detection windows for most peptides Dried blood spots: Emerging method with good sensitivity Hair: Not commonly used for peptides but theoretically possible Most anti-doping testing uses urine

Also known as: 1401708-83-5, L-isoleucinamide, n-(1-oxohexyl)-l-tyrosyl-n-(6-amino-6-oxohexyl)-, 9wyx65a5c2, N-hexanoic-tyr-ile-(6) aminohexanoic amide, Pnb-0408, 6-(2-(2-hexanamido-3-(4-hydroxyphenyl)propanamido)-3-methylpentanamido)hexanamide Molecular Formula C 27 H 44 N 4 O 5 Molecular Weight 504.7 g/mol InChI Key XEUVNVNAVKZSPT-JTJYXVOQSA-N 1 2D Structure 2 Identification 2.1 Computed Descriptors 2.1.1 IUPAC Name (2S,3S)-N-(6-amino-6-oxohexyl)-2-[[(2S)-2-(hexanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanamide 2.1.2 InChI InChI=1S/C27H44N4O5/c1-4-6-8-12-24(34)30-22(18-20-13-15-21(32)16-14-20)26(35)31-25(19(3)5-2)27(36)29-17-10-7-9-11-23(28)33/h13-16,19,22,25,32H,4-12,17-18H2,1-3H3,(H2,28,33)(H,29,36)(H,30,34)(H,31,35)/t19-,22-,25-/m0/s1 2.1.3 InChI Key XEUVNVNAVKZSPT-JTJYXVOQSA-N 2.1.4 Canonical SMILES CCCCCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C(C)CC)C(=O)NCCCCCC(=O)N 2.1.5 Isomeric SMILES CCCCCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCCCCCC(=O)N 2.2 Other Identifiers 2.2.1 UNII 2.3 Synonyms 2.3.1 MeSH Synonyms 1

Longterm storage is recommended at 20C, although shortterm stability may be maintained at 28C when protected from moisture and light